To observe the effect of breast cancer postoperative prescription on the quality of life, tumor markers and peripheral blood T lymphocyte subsets in patients with breast cancer after operation. From June 2017 to June 2018, 100 patients who were admitted to our hospital with long-term outpatient follow-up with breast cancer after operation were selected, and they were divided into control group (50 cases) and experimental group (50 cases) according to the double chromosphere method. The control group received routine standardized treatment of Western medicine, and the experimental group after operation received breast cancer postoperative prescription treatment on this basis. 1 year after treatment, the efficacy, quality of life, tumor markers, peripheral blood T cell subsets and 3-year disease-free survival rate were compared between the two groups. The total clinical effective rate in the experimental group was 84.00% (42/50), which was better than 56.00% (28/50) in the control group, there was significant difference between the groups (P<0.05). After treatment, the scores of symptom field were lower than those in the control group, and the scores of overall health status and functional field in the experimental group were higher than those in the control group (P<0.05). After treatment, the levels of serum carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and tumor specific growth factor (TSGF) in the experimental group were lower than those in the control group (P<0.05). Compared with the control group, CD3+, CD4+, CD4+/CD8+in the experimental group after treatment increased, and CD8+ decreased (P<0.05). The 3-year disease-free survival rate in the experimental group was higher than that in the control group (P<0.05). The patients with breast cancer after operation use breast cancer postoperative prescription on the basis of conventional standardized treatment has a good effect, which can effectively control cancer, improve immune function, promote the improvement of life quality, and improve the 3-year disease-free survival rate. [ABSTRACT FROM AUTHOR]